These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38617221)

  • 1. Distal Protein-Protein Interactions Contribute to SARS-CoV-2 Main Protease Substrate Binding and Nirmatrelvir Resistance.
    Lewandowski EM; Zhang X; Tan H; Jaskolka-Brown A; Kohaal N; Frazier A; Madsen JJ; Jacobs LMC; Wang J; Chen Y
    bioRxiv; 2024 Apr; ():. PubMed ID: 38617221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir.
    Kiso M; Furusawa Y; Uraki R; Imai M; Yamayoshi S; Kawaoka Y
    Nat Commun; 2023 Jul; 14(1):3952. PubMed ID: 37402789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor
    Jochmans D; Liu C; Donckers K; Stoycheva A; Boland S; Stevens SK; De Vita C; Vanmechelen B; Maes P; Trüeb B; Ebert N; Thiel V; De Jonghe S; Vangeel L; Bardiot D; Jekle A; Blatt LM; Beigelman L; Symons JA; Raboisson P; Chaltin P; Marchand A; Neyts J; Deval J; Vandyck K
    mBio; 2023 Feb; 14(1):e0281522. PubMed ID: 36625640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replication capacity and susceptibility of nirmatrelvir-resistant mutants to next-generation Mpro inhibitors in a SARS-CoV-2 replicon system.
    Lo CW; Kariv O; Hao C; Gammeltoft KA; Bukh J; Gottwein J; Westberg M; Lin MZ; Einav S
    Antiviral Res; 2024 Nov; 231():106022. PubMed ID: 39424074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system.
    Zhou Y; Gammeltoft KA; Ryberg LA; Pham LV; Tjørnelund HD; Binderup A; Duarte Hernandez CR; Fernandez-Antunez C; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
    Sci Adv; 2022 Dec; 8(51):eadd7197. PubMed ID: 36542720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of SARS-CoV-2 Main Protease Mutations at Positions L50, E166, and L167 Rendering Resistance to Covalent and Noncovalent Inhibitors.
    Kovalevsky A; Aniana A; Ghirlando R; Coates L; Drago VN; Wear L; Gerlits O; Nashed NT; Louis JM
    J Med Chem; 2024 Oct; 67(20):18478-18490. PubMed ID: 39370853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanism-Driven Discovery of Novel Small Molecule Inhibitors against Drug-Resistant SARS-CoV-2 M
    Yang J; Fu B; Gou R; Lin X; Wu H; Xue W
    J Chem Inf Model; 2024 Oct; 64(20):7998-8009. PubMed ID: 39387184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
    Iketani S; Mohri H; Culbertson B; Hong SJ; Duan Y; Luck MI; Annavajhala MK; Guo Y; Sheng Z; Uhlemann AC; Goff SP; Sabo Y; Yang H; Chavez A; Ho DD
    bioRxiv; 2022 Aug; ():. PubMed ID: 36032976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants.
    Jiang H; Zhou Y; Zou X; Hu X; Wang J; Zeng P; Li W; Zeng X; Zhang J; Li J
    Biochemistry; 2023 Jul; 62(13):2055-2064. PubMed ID: 37222536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
    Iketani S; Mohri H; Culbertson B; Hong SJ; Duan Y; Luck MI; Annavajhala MK; Guo Y; Sheng Z; Uhlemann AC; Goff SP; Sabo Y; Yang H; Chavez A; Ho DD
    Nature; 2023 Jan; 613(7944):558-564. PubMed ID: 36351451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.
    Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K
    EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance.
    Zhu Y; Yurgelonis I; Noell S; Yang Q; Guan S; Li Z; Hao L; Rothan H; Rai DK; McMonagle P; Baniecki ML; Greasley SE; Plotnikova O; Lee J; Nicki JA; Ferre R; Byrnes LJ; Liu W; Craig TK; Steppan CM; Liberator P; Soares HD; Allerton CMN; Anderson AS; Cardin RD
    Sci Adv; 2024 Jul; 10(30):eadl4013. PubMed ID: 39047088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir.
    Hu Y; Lewandowski EM; Tan H; Zhang X; Morgan RT; Zhang X; Jacobs LMC; Butler SG; Gongora MV; Choy J; Deng X; Chen Y; Wang J
    ACS Cent Sci; 2023 Aug; 9(8):1658-1669. PubMed ID: 37637734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nirmatrelvir Resistance in SARS-CoV-2 Omicron_BA.1 and WA1 Replicons and Escape Strategies.
    Lan S; Neilsen G; Slack RL; Cantara WA; Castaner AE; Lorson ZC; Lulkin N; Zhang H; Lee J; Cilento ME; Tedbury PR; Sarafianos SG
    bioRxiv; 2023 Jan; ():. PubMed ID: 36656782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir.
    Hu Y; Lewandowski EM; Tan H; Zhang X; Morgan RT; Zhang X; Jacobs LMC; Butler SG; Gongora MV; Choy J; Deng X; Chen Y; Wang J
    bioRxiv; 2022 Sep; ():. PubMed ID: 36119652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir.
    Krismer L; Schöppe H; Rauch S; Bante D; Sprenger B; Naschberger A; Costacurta F; Fürst A; Sauerwein A; Rupp B; Kaserer T; von Laer D; Heilmann E
    Npj Viruses; 2024; 2(1):23. PubMed ID: 38933182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes.
    Padhi AK; Tripathi T
    Biochem Biophys Res Commun; 2022 Nov; 629():54-60. PubMed ID: 36113178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive Mutation in the Main Protease Cleavage Site of Feline Coronavirus Renders the Virus More Resistant to Main Protease Inhibitors.
    Jiao Z; Yan Y; Chen Y; Wang G; Wang X; Li L; Yang M; Hu X; Guo Y; Shi Y; Peng G
    J Virol; 2022 Sep; 96(17):e0090722. PubMed ID: 36000844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributions of Hyperactive Mutations in M
    Flynn JM; Zvornicanin SN; Tsepal T; Shaqra AM; Kurt Yilmaz N; Jia W; Moquin S; Dovala D; Schiffer CA; Bolon DNA
    ACS Infect Dis; 2024 Apr; 10(4):1174-1184. PubMed ID: 38472113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.